Schrödinger Q1 ACV $28.4M (+12%), drug disc. rev surges to $22.9M, net loss $60M, FY guide maintained

Schrodinger, Inc.

2026-Q1 EPS reported -$0.81 revenue$58,587,000

ACV $28.4M (+12% YoY); software revenue $35.6M (-21%) reflecting hosted transition.
Drug discovery revenue surged to $22.9M from $10.2M on deferred revenue recognition and program discontinuation.
Net loss $60.0M vs $59.8M; cash and securities $406M.
Maintained FY2026 guidance: ACV $218-228M (10-15% growth), drug discovery revenue $55-65M.
Planned summer launch of Bunsen agentic AI co-scientist; Lilly's $2.3B Ajax acquisition validates platform.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.